personally i wouldnt buy this while it is in a consistent downtrend. when are they going to finish the RX5 phase 3 trials? they are kinda being silent on this - previous presentations indicated 300 patients enrolled in 1H 2023 for completion by 2H 2023. no update so far on number of patients enrolled and whether they are still on track. all this R&D occurring in the background is fine but not as important as getting to commercialisation and cash in the door.
Ann: Emyria Grows MDMA Asset for Neuro & Mental Health Therapy, page-3
Add to My Watchlist
What is My Watchlist?
